Elvina® – Bioequivalent to Yasmin®

Packet of Elvina contraceptives

  • Contains 0.03mg ethinylestradiol and 3mg drospirenone, exactly the same active ingredients as Yasmin®¹-² 
  • Indicated for the prevention of pregnancy in women who elect to use an oral contraceptive¹
  • Inhibits ovulation & causes changes in the endometrium¹
  • Contains drospirenone which exhibits both antiandrogenic & antimineralocorticoid properties¹
  • Drospirenone has a pharmacological profile resembling the natural hormone progesterone¹
  • Is highly effective when taken correctly & consistently¹-⁴
  • ELVINA® has a Pearl Index of 0.57¹
  • Contains soya lecithin – patients with allergies to soya or peanut should not be prescribed ELVINA®1
  • ELVINA® is non GMS reimbursed

ELVINA® is suitable for use in the following patient groups:⁵-⁶

  • Women who want autonomy and control over their menstrual cycle
  • Women aged up to 50 years with no other medical conditions
  • Women with a BMI of ≤34kg/m2 who do not smoke
  • Women ≥6 months postpartum if fully breast feeding
  • Women ≥6 weeks postpartum if not breast feeding
  • Women with dysmenorrhoea who have an irregular, heavy or prolonged bleeding pattern
  • Women with endometriosis

References:

1. Elvina® SmPC
2. Yasmin® SmPC
available at www.medicines.ie
3. MIMS Ireland (August 2017) ‘Contraception’ MPI Media Ltd, Dublin.
4. Krattenmacher, R. 2000 Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul;62(1):29-38.
5. WHO Guidelines. Medical Eligibility Criteria for contraceptive use 2015 update.
6. Faculty of Sexual and Reproductive Health Care (FSRH). UK Medical Eligibility Criteria for Contraceptive Use. UKMEC 2016. London: FSRH, 2016.

IE/OCS/0817/0058c Date of preparation: July 2018

Web design by Enhance.ie

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close